COMPOUND WITH CONFIDENCE: PCCA Membership, $895/month.

Pharmacy compounding's source for clinical information, regulatory updates, and opportunities

THE PCCA BLOG

rss

Stay current on PCCA news and events, market trends, and all things compounding!

2025-01_BLOG_Stealth Syndrome_Banner_800w.jpg

A forthcoming documentary from the LDN Research Trust gives compounding pharmacists, physicians and prescribers an opportunity to learn about a group of complex and debilitating syndromes that affect one in six Americans — syndromes that occur in almost every part of the body, often accompany each other and collectively exacerbate the patient’s pain and other symptoms. This article briefly summarizes these syndromes and their overlapping symptoms and discusses how you can help educate providers in your community — as well as your staff and patients — about their effects, along with the potential use of low-dose naltrexone (LDN) in compounding preparations.

BB_Bacterial Vaginosis_800w.jpg

Bacterial vaginosis (BV) is the most common vaginal infection that affects women around the globe. In addition to its effects on total health, BV can significantly impact reproductive wellness. The condition is thought to originate from a decrease of Lactobacilli in the vagina, resulting in an imbalance in the natural vaginal microbiome.1 In the following article, we explore the pathogens associated with BV and challenges with commercial treatments, as well as compounding options and an innovative base that may potentially improve patient compliance.

202501_BB-SuspendIT_800w.jpg

Suspensions are pharmaceutical dosage forms consisting of insoluble active ingredients dispersed in a base vehicle. An ideal suspension should be uniform in content so each dose contains an equivalent amount of one or more — most likely one — active pharmaceutical ingredients (APIs). We briefly review oral suspensions and why content uniformity is vital in compounded preparations, as well as showcase the most studied oral suspension, in the following article.

BB_HRT Master Course_823x462.jpg

The numbers are in — forecasters predict 1.1 billion women worldwide will experience menopause in 2025. In the U.S., more than 1 million women reach menopause each year, and more than 75 percent of these women are employed during menopause transition years. Research conducted by the National Institute on Aging indicates menopausal hormone therapy (MHT) reduced the severity of menopause symptoms while elevating mood, sexual function, cardiovascular and brain health.

BB_EctoSeal-Nail Fungus_800w.jpg

One of the most valuable benefits of PCCA membership is access to our knowledgeable Research & Development department and their compounding base innovations. Their creativity has led the industry and provided resources that benefit thousands of patients every day. This post focuses on a powerful base launched in 2023, EctoSeal P2G, and its application in one of the most common dermatological conditions — nail fungus (onychomycosis).

BB_Microdosing-GLP-1RAs_823x462.jpg

Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have revolutionized metabolic health and weight management, leading to a host of new weight loss wonder drugs. But did you know that recent evidence shows these new drugs may do more than just help with weight loss and diabetes? And at a fraction of the standard dose?

BB_LDN-Virtual-Conference_823x462.jpg

Individuals who suffer from symptoms of gastrointestinal, autoimmune, dermatological and pain conditions make up 80% of the patient population. But here’s the good news: multiple studies indicate that low-dose naltrexone (LDN) may potentially help many of these conditions. Take a sneak peek at topics our Clinical Services team will discuss during the Low-Dose Naltrexone One-Day Virtual Conference on Thursday, November 21, 2024.

2024011_BB_Perimenopause_823x462.jpg

Perimenopause is a unique phase in a woman’s life, marked by fluctuating hormones and a wide range of symptoms. Hormone replacement therapy (HRT) can offer relief, but a one-size-fits-all approach may not yield the best results. A personalized approach, tailored to each woman’s unique hormonal profile, lifestyle and symptoms, can make all the difference in managing this transition effectively. Let’s explore the factors that contribute to low estrogen, the role of cortisol and progesterone, and why a customized approach to HRT is essential for perimenopausal women.

BB_Backed-by-PCCA-Science_823x462.jpg

At PCCA Science, we continuously build and grow scientific support for compounding and the technologies our members use in their practices. We test our bases using various methods before, during and after the release of a new product. We regularly submit results of these studies for publication in peer-reviewed journals and make them available to our members, who in turn can share them with prescribers, physicians and patients.

BB_Sebastian-LDN Webinar_800w.jpg

Since 2014, there’s been an explosion of information about the potential applications of low-dose naltrexone (LDN), including use as an adjunct therapeutic in some types of cancer. The exploration of LDN in cancer treatment underscores the importance of understanding the complex interplay between immune signaling and cancer biology, which we discuss in the following article.